0000000000349640

AUTHOR

Galvano Antonio

showing 3 related works from this author

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Itali…

2022

Constitutional BRCA1/BRCA2 pathogenic or likely pathogenic variants (PVs) are associated with an increased risk for developing breast and ovarian cancers. Current evidence indicates that BRCA1/2 PVs are also associated with pancreatic cancer, and that BRCA2 PVs are associated with prostate cancer risk. The identification of carriers of constitutional PVs in the BRCA1/2 genes allows the implementation of individual and family prevention pathways, through validated screening programs and risk-reducing strategies. According to the relevant and increasing therapeutic predictive implications, the inclusion of BRCA testing in the routine management of patients with breast, ovarian, pancreatic and…

Societies ScientificMaleOvarian NeoplasmsCancer Researchgenetic counselingBRCABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinomaProstatic Neoplasmspancreatic ductal adenocarcinomaScientificSettore MED/03 - GENETICA MEDICABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinoma; Female; Humans; Italy; Male; Societies Scientific; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic NeoplasmsBRCA1BRCA2BRCA-related cancerPancreatic NeoplasmsBRCA testingPARP inhibitorOncologyItalyHumansFemaleSocietiesPARP inhibitors
researchProduct

Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizu…

2017

Immune-checkpoint inhibitors represent the new standard of care in patients with advanced NSCLC who progressed after first-line treatment. This work aim to assess any difference in both efficacy and safety profiles among Nivolumab, Pembrolizumab and Atezolizumab in pre-treated NSCLC patients. Randomized clinical trials comparing immune-checkpoint inhibitor versus docetaxel in pre-treated patients with advanced NSCLC were included and direct comparison meta-analysis of selected trials have been performed. Subsequently the summary estimates of Nivolumab, Pembrolizumab and Atezolizumab emerging from the direct meta-analysis were selected to provide the pooled estimates of hazard ratio (HR) and…

atezolizumabCancer ResearchLung NeoplasmsAntineoplastic AgentsDocetaxelAntibodies Monoclonal HumanizedNSCLCClinical Trials Phase II as TopicCostimulatory and Inhibitory T-Cell ReceptorsCarcinoma Non-Small-Cell LungPDL1HumansRandomized Controlled Trials as TopicnivolumabIncidenceAntibodies MonoclonalPneumoniaSurvival AnalysisPD1Treatment OutcomeClinical Trials Phase III as TopicOncologyimmune-checkpointTaxoidsatezolizumab; immune-checkpoint; nivolumab; NSCLC; PD1; PDL1; pembrolizumab; Oncology; Cancer Researchpembrolizumab
researchProduct

Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare

2022

immunocompromised patientCancer ResearchOncologySARS-CoV-2COVID-19healthcare (MeSH)CancerFrontiers in Oncology
researchProduct